Proqr Therapeutics (PRQR)

$1.89 +0.11 (6.18%)
Market Cap 187.28M
Revenue (ttm) 20.46M
Net Income (ttm) -30.04M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -146.82%
Debt to Equity Ratio 0.08
Volume 648,689
Avg Vol 429,084
Day's Range N/A - N/A
Shares Out 105.21M
Stochastic %K 97%
Beta 0.21
Analysts Strong Sell
Price Target $8.88

Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Re...

Industry: Biotechnology
Sector: Healthcare
Phone: 31 88 166 7000
Address:
Zernikedreef 9, Leiden, Netherlands
ehpats
ehpats Mar. 9 at 5:04 PM
$PRQR slow and steady is fine with me. 5% per day from here to $4
0 · Reply
Bionco
Bionco Mar. 9 at 2:03 PM
$PRQR alright accumulation was done . Will hold for the data readouts by the mid year
0 · Reply
buymoremakemore
buymoremakemore Mar. 7 at 8:41 PM
$PRQR In wth 30k shares in $1.70 range. Still low considering how high with these rich catalysts!
0 · Reply
Filvul
Filvul Mar. 6 at 6:15 AM
$PRQR
0 · Reply
LeftyT
LeftyT Mar. 5 at 4:16 AM
$PRQR Nice to see someone is paying attention to this stock..... finally.
1 · Reply
Filvul
Filvul Mar. 4 at 7:20 AM
$PRQR what kind of conference next week?
1 · Reply
ehpats
ehpats Mar. 3 at 10:55 PM
$PRQR maybe news coming before the conference next week? 🤞🤞🤞 We need a data update.
0 · Reply
focafoca99
focafoca99 Mar. 3 at 10:46 PM
$PRQR webcast at Citizens Life Sciences puts management back in front of investors. Could get interesting with any pipeline color.
0 · Reply
focafoca99
focafoca99 Mar. 3 at 10:37 PM
$PRQR webcast at Citizens Life Sciences puts management back in front of investors. Could get interesting with any pipeline color.
0 · Reply
Filvul
Filvul Feb. 27 at 7:36 PM
$PRQR this will fly soon:)
1 · Reply
Latest News on PRQR
ProQR Announces Webcast of Presentation at the 2026 Citizens Life Sciences Conference

Mar 3, 2026, 4:30 PM EST - 5 days ago

ProQR Announces Webcast of Presentation at the 2026 Citizens Life Sciences Conference

ProQR Announces Planned Changes to Board Composition

Feb 9, 2026, 8:00 AM EST - 4 weeks ago

ProQR Announces Planned Changes to Board Composition

ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook

Jan 8, 2026, 8:00 AM EST - 2 months ago

ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook

ProQR to Participate in 8th Annual Evercore Healthcare Conference

Dec 1, 2025, 8:00 AM EST - 3 months ago

ProQR to Participate in 8th Annual Evercore Healthcare Conference

ProQR Announces Third Quarter 2025 Operating and Financial Results

Nov 6, 2025, 7:00 AM EST - 4 months ago

ProQR Announces Third Quarter 2025 Operating and Financial Results

ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call Transcript

Nov 3, 2025, 6:46 PM EST - 4 months ago

ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call Transcript

ProQR Receives CTA Authorization for AX-0810 and Announces Virtual Investor and Analyst Event on November 3, 2025

Oct 20, 2025, 8:00 AM EDT - 5 months ago

ProQR Receives CTA Authorization for AX-0810 and Announces Virtual Investor and Analyst Event on November 3, 2025

ProQR to Participate in Upcoming Investor Conferences in October 2025

Oct 13, 2025, 8:30 AM EDT - 5 months ago

ProQR to Participate in Upcoming Investor Conferences in October 2025

ProQR Announces Second Quarter 2025 Operating and Financial Results

Aug 7, 2025, 7:00 AM EDT - 7 months ago

ProQR Announces Second Quarter 2025 Operating and Financial Results

ProQR Announces Upcoming Presentation at RNA Editing Summit

Jul 28, 2025, 8:00 AM EDT - 8 months ago

ProQR Announces Upcoming Presentation at RNA Editing Summit

ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP

Jun 26, 2025, 4:30 PM EDT - 9 months ago

ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP

ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences

May 12, 2025, 8:00 AM EDT - 10 months ago

ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences

ProQR Announces First Quarter 2025 Operating and Financial Results

May 8, 2025, 7:00 AM EDT - 10 months ago

ProQR Announces First Quarter 2025 Operating and Financial Results

ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference

May 2, 2025, 8:00 AM EDT - 11 months ago

ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference

ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025

May 1, 2025, 8:00 AM EDT - 11 months ago

ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025

ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth

Apr 14, 2025, 7:00 AM EDT - 11 months ago

ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth

ProQR Announces Year End 2024 Operating and Financial Results

Mar 13, 2025, 7:00 AM EDT - 1 year ago

ProQR Announces Year End 2024 Operating and Financial Results

ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist

Dec 10, 2024, 8:00 AM EST - 1 year ago

ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist

ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement

Oct 25, 2024, 4:45 PM EDT - 1 year ago

ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement

ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement

Oct 22, 2024, 10:15 PM EDT - 1 year ago

ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement

ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares

Oct 22, 2024, 4:01 PM EDT - 1 year ago

ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares

ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society

Oct 7, 2024, 8:00 AM EDT - 1 year ago

ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society

ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference

Sep 10, 2024, 4:30 PM EDT - 1 year ago

ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference

ProQR Therapeutics N.V. (PRQR) ASGCT Investor Webcast (Transcript)

May 11, 2024, 5:57 PM EDT - 1 year ago

ProQR Therapeutics N.V. (PRQR) ASGCT Investor Webcast (Transcript)

ProQR Announces First Quarter 2024 Operating and Financial Results

May 9, 2024, 7:00 AM EDT - 1 year ago

ProQR Announces First Quarter 2024 Operating and Financial Results

ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024

Apr 23, 2024, 7:00 AM EDT - 2 years ago

ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024

ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting

Apr 22, 2024, 4:31 PM EDT - 2 years ago

ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting

ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio

Apr 19, 2024, 7:00 AM EDT - 2 years ago

ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio

ProQR Announces Year End 2023 Operating and Financial Results

Mar 13, 2024, 7:00 AM EDT - 2 years ago

ProQR Announces Year End 2023 Operating and Financial Results

ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024

Jan 19, 2024, 7:00 AM EST - 2 years ago

ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024

ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration

Jan 5, 2024, 7:00 AM EST - 2 years ago

ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration

ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets

Dec 8, 2023, 7:30 AM EST - 2 years ago

ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets

ProQR Announces Third Quarter 2023 Operating and Financial Results

Nov 7, 2023, 7:00 AM EST - 2 years ago

ProQR Announces Third Quarter 2023 Operating and Financial Results

ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing

Nov 6, 2023, 7:00 AM EST - 2 years ago

ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing

ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference

Sep 28, 2023, 8:00 AM EDT - 2 years ago

ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference

ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference

Sep 7, 2023, 8:00 AM EDT - 2 years ago

ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference

ProQR Announces Second Quarter 2023 Operating and Financial Results

Aug 3, 2023, 7:00 AM EDT - 2 years ago

ProQR Announces Second Quarter 2023 Operating and Financial Results

ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR's Sepofarsen and Ultevursen Ophthalmic Assets

Aug 1, 2023, 7:00 AM EDT - 2 years ago

ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR's Sepofarsen and Ultevursen Ophthalmic Assets

ProQR: Too Many Failures For Its RNA Technology

Jul 9, 2023, 6:53 AM EDT - 2 years ago

ProQR: Too Many Failures For Its RNA Technology

ProQR to Present Data on its Axiomer® RNA Editing Technology at RNA Editing Summit

Jul 6, 2023, 7:00 AM EDT - 2 years ago

ProQR to Present Data on its Axiomer® RNA Editing Technology at RNA Editing Summit

ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023

May 9, 2023, 8:00 AM EDT - 3 years ago

ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023

ProQR Announces Upcoming Investor Conferences in April and May

Apr 20, 2023, 8:00 AM EDT - 3 years ago

ProQR Announces Upcoming Investor Conferences in April and May

ProQR Announces Annual Meeting of Shareholders to be Held May 17, 2023

Apr 18, 2023, 8:00 AM EDT - 3 years ago

ProQR Announces Annual Meeting of Shareholders to be Held May 17, 2023

ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event

Mar 29, 2023, 8:00 AM EDT - 3 years ago

ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event

ProQR Announces Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing

Mar 14, 2023, 8:00 AM EDT - 3 years ago

ProQR Announces Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing

ProQR to Present at Upcoming Scientific and Industry Conferences

Mar 7, 2023, 8:00 AM EST - 3 years ago

ProQR to Present at Upcoming Scientific and Industry Conferences

ProQR's stock jumps on expanded RNA deal with Lilly

Dec 22, 2022, 9:12 AM EST - 3 years ago

ProQR's stock jumps on expanded RNA deal with Lilly

LLY

ProQR Announces Conference Call to Discuss Axiomer® RNA Editing Platform

Dec 22, 2022, 6:15 AM EST - 3 years ago

ProQR Announces Conference Call to Discuss Axiomer® RNA Editing Platform

Lilly and ProQR to Expand RNA Editing Collaboration

Dec 22, 2022, 6:00 AM EST - 3 years ago

Lilly and ProQR to Expand RNA Editing Collaboration

LLY

ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022

Nov 14, 2022, 4:30 PM EST - 3 years ago

ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022

ehpats
ehpats Mar. 9 at 5:04 PM
$PRQR slow and steady is fine with me. 5% per day from here to $4
0 · Reply
Bionco
Bionco Mar. 9 at 2:03 PM
$PRQR alright accumulation was done . Will hold for the data readouts by the mid year
0 · Reply
buymoremakemore
buymoremakemore Mar. 7 at 8:41 PM
$PRQR In wth 30k shares in $1.70 range. Still low considering how high with these rich catalysts!
0 · Reply
Filvul
Filvul Mar. 6 at 6:15 AM
$PRQR
0 · Reply
LeftyT
LeftyT Mar. 5 at 4:16 AM
$PRQR Nice to see someone is paying attention to this stock..... finally.
1 · Reply
Filvul
Filvul Mar. 4 at 7:20 AM
$PRQR what kind of conference next week?
1 · Reply
ehpats
ehpats Mar. 3 at 10:55 PM
$PRQR maybe news coming before the conference next week? 🤞🤞🤞 We need a data update.
0 · Reply
focafoca99
focafoca99 Mar. 3 at 10:46 PM
$PRQR webcast at Citizens Life Sciences puts management back in front of investors. Could get interesting with any pipeline color.
0 · Reply
focafoca99
focafoca99 Mar. 3 at 10:37 PM
$PRQR webcast at Citizens Life Sciences puts management back in front of investors. Could get interesting with any pipeline color.
0 · Reply
Filvul
Filvul Feb. 27 at 7:36 PM
$PRQR this will fly soon:)
1 · Reply
Bionco
Bionco Feb. 25 at 9:35 PM
$PRQR added at this level
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 22 at 11:16 AM
$PRQR Current Stock Price: $1.43 Contracts to trade: $2.5 PRQR Mar 20 2026 Call Entry: $0.09 Exit: $0.16 ROI: 73% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 22 at 3:49 AM
$PRQR Current Stock Price: $1.43 Contracts to trade: $2.5 PRQR Mar 20 2026 Call Entry: $0.09 Exit: $0.15 ROI: 66% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 21 at 6:19 PM
$PRQR RSI: 34.48, MACD: -0.1018 Vol: 0.10, MA20: 1.53, MA50: 1.82 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
dirkfrank
dirkfrank Feb. 20 at 5:23 PM
$PRQR fully controlled
2 · Reply
Aciputes
Aciputes Feb. 20 at 1:42 PM
$PRQR
1 · Reply
KostasBars
KostasBars Feb. 20 at 1:17 PM
$PRQR big jump. Any news
2 · Reply
anlkrts
anlkrts Feb. 19 at 8:01 PM
$PRQR is earning realese today or not?
0 · Reply
Geert07
Geert07 Feb. 12 at 6:21 PM
$PRQR I started adding small batches between 1.60 and 1.35. Let’s see how far it will drop.
1 · Reply
ehpats
ehpats Feb. 12 at 2:13 PM
$PRQR wonder if we will get preliminary data on the additional cohorts? Seem like that data should be known by late February.
1 · Reply
dirkfrank
dirkfrank Feb. 12 at 3:51 AM
$PRQR pffff jeez
0 · Reply
RandomInvestor777
RandomInvestor777 Feb. 9 at 7:23 PM
$PRQR Board changes. probably to get van herk off their backs... except it's not the ones van herk named.... well its progress at least https://www.proqr.com/press-releases/proqr-announces-planned-changes-to-board-composition
2 · Reply